New Weight Loss Drug Achieves Surgery-Level Results

People battling severe obesity just gained a powerful new ally in their fight for better health.

Eli Lilly announced results from a major clinical trial of retatrutide, a first-of-its-kind medication that helped participants lose an average of 70 pounds over 80 weeks. Nearly half of those on the highest dose lost 30% or more of their body weight, a milestone previously associated only with weight loss surgery.

The trial, called TRIUMPH-1, tested three different doses on adults with obesity or overweight conditions who also had at least one related health problem but no diabetes. At the lowest dose, requiring just one escalation step, participants still lost an average of 47 pounds.

What makes retatrutide unique is how it works. The drug targets three different hormone receptors at once (GIP, GLP-1, and glucagon), making it more comprehensive than current medications like Zepbound that target two receptors.

Dr. Ania Jastreboff, who led the study at Yale School of Medicine, called the results impressive. She emphasized that obesity is a chronic disease with complex biology, and people deserve treatment options that match that complexity.

The results extended beyond the scale. Participants saw meaningful improvements in heart health markers, including waist size, cholesterol levels, blood pressure, and inflammation indicators. More than 65% of people taking the highest dose dropped below the obesity threshold for BMI, including over a third of those who started with severe obesity.

Why This Inspires

These results represent more than just numbers on a scale. For the estimated 42% of American adults living with obesity, finding effective treatment has been an uphill battle filled with stigma and limited options.

Retatrutide offers something revolutionary: choice. With three effective dose levels, doctors and patients can work together to find the right balance between results and tolerability. Some people may prefer the lower dose with its easier escalation, while others may benefit from higher doses for more dramatic results.

The trial also included a two-year extension for people with severe obesity, where participants on the highest dose lost an average of 85 pounds. That sustained weight loss matters because obesity management is a marathon, not a sprint.

Beyond weight loss, the cardiovascular improvements could reduce risks for heart disease, stroke, and other life-threatening conditions. That means more years of health and vitality for people who've struggled with their weight.

Lilly already offers two obesity medications, and adding retatrutide to that lineup would give healthcare providers more tools to personalize treatment. Different people respond differently to medications, so having multiple options increases the chances that everyone can find something that works for them.

The medication still needs FDA approval before reaching patients, but these Phase 3 results mark a major step forward in treating obesity as the serious medical condition it is.